Details of the Drug

General Information of Drug (ID: DM3906J)

Drug Name

Bedaquiline

Synonyms

SIRTURO (TN)

Indication

Disease Entry	ICD 11	Status	REF
Multi-drug resistant tuberculosis	MG52.00	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

555.5

Topological Polar Surface Area (xlogp)

7.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 64.75 mgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 5.5 mg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5 h [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 5.5 months [4]
Metabolism: The drug is metabolized via the hepatic [3]
Vd: The volume of distribution (Vd) of drug is 164 L [5]

Chemical Identifiers

Formula: C32H31BrN2O2
IUPAC Name: (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol
Canonical SMILES: CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O
InChI: InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1
InChIKey: QUIJNHUBAXPXFS-XLJNKUFUSA-N

Cross-matching ID

PubChem CID: 5388906
ChEBI ID: CHEBI:72292
CAS Number: 843663-66-1
DrugBank ID: DB08903
TTD ID: D0Y4QG
INTEDE ID: DR0182
ACDINA ID: D00059

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mycobacterium Proton pump (MycB Prop)	TT19K0L	A0A1Q4HQH4_9MYCO	Modulator	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bedaquiline (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[16]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Ivosidenib.	Acute myeloid leukaemia [2A60]	[17]
Tagraxofusp	DM9HQ5U	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Tagraxofusp.	Acute myeloid leukaemia [2A60]	[18]
Arn-509	DMT81LZ	Major	Increased metabolism of Bedaquiline caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[19]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Gilteritinib.	Acute myeloid leukaemia [2A60]	[18]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Oliceridine.	Acute pain [MG31]	[20]
Inotersen	DMJ93CT	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Inotersen.	Amyloidosis [5D00]	[18]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Bedaquiline and Ivabradine.	Angina pectoris [BA40]	[19]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Bedaquiline and Levalbuterol.	Asthma [CA23]	[21]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Bedaquiline caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Bedaquiline and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[22]
LY2835219	DM93VBZ	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and LY2835219.	Breast cancer [2C60-2C6Y]	[18]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Bedaquiline caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[18]
Macitentan	DMP79A1	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Macitentan.	Cardiovascular disease [BA00-BE2Z]	[18]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[18]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Bedaquiline and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Bedaquiline and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Intedanib	DMSTA36	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Intedanib.	Colorectal cancer [2B91]	[18]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Osilodrostat.	Cushing syndrome [5A70]	[18]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Bedaquiline caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[19]
Polatuzumab vedotin	DMF6Y0L	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[18]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Deutetrabenazine.	Dystonic disorder [8A02]	[18]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Ingrezza.	Dystonic disorder [8A02]	[18]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Bedaquiline caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Eslicarbazepine	DMZREFQ	Major	Increased metabolism of Bedaquiline caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Cannabidiol.	Epileptic encephalopathy [8A62]	[18]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Bedaquiline caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[25]
177Lu-DOTATATE	DMT8GVU	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[18]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Bedaquiline caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Givosiran	DM5PFIJ	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[18]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Bedaquiline and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[26]
Lurbinectedin	DMEFRTZ	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Lurbinectedin.	Lung cancer [2C25]	[18]
PF-06463922	DMKM7EW	Major	Increased metabolism of Bedaquiline caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[19]
Alectinib	DMP1I6Y	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Alectinib.	Lung cancer [2C25]	[18]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Osimertinib.	Lung cancer [2C25]	[18]
BIBW 2992	DMTKD7Q	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and BIBW 2992.	Lung cancer [2C25]	[18]
Pralsetinib	DMWU0I2	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Pralsetinib.	Lung cancer [2C25]	[18]
Capmatinib	DMYCXKL	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Capmatinib.	Lung cancer [2C25]	[18]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Selpercatinib.	Lung cancer [2C25]	[18]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[18]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Idelalisib.	Mature B-cell leukaemia [2A82]	[27]
IPI-145	DMWA24P	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and IPI-145.	Mature B-cell leukaemia [2A82]	[18]
Blinatumomab	DMGECIJ	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Blinatumomab.	Mature B-cell lymphoma [2A85]	[18]
Arry-162	DM1P6FR	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Arry-162.	Melanoma [2C30]	[18]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and LGX818.	Melanoma [2C30]	[18]
Dabrafenib	DMX6OE3	Major	Increased metabolism of Bedaquiline caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[19]
Tecfidera	DM2OVDT	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Tecfidera.	Multiple sclerosis [8A40]	[18]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Bedaquiline and Siponimod.	Multiple sclerosis [8A40]	[16]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Bedaquiline and Ozanimod.	Multiple sclerosis [8A40]	[28]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Bedaquiline caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[19]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Entrectinib.	Non-small cell lung cancer [2C25]	[18]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Rucaparib.	Ovarian cancer [2C73]	[18]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Triclabendazole.	Parasitic worm infestation [1F90]	[18]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Bedaquiline caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[29]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[30]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Lefamulin.	Pneumonia [CA40]	[31]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Relugolix.	Prostate cancer [2C82]	[18]
Sarilumab	DMOGNXY	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Sarilumab.	Rheumatoid arthritis [FA20]	[18]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Bedaquiline caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[32]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Bedaquiline caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[18]
Larotrectinib	DM26CQR	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[18]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[18]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Pitolisant.	Somnolence [MG42]	[18]
Fostamatinib	DM6AUHV	Moderate	Increased risk of hepatotoxicity by the combination of Bedaquiline and Fostamatinib.	Thrombocytopenia [3B64]	[18]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Bedaquiline and Lenvatinib.	Thyroid cancer [2D10]	[18]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Bedaquiline caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[18]
-----------


⏷ Show the Full List of 68 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium stearyl fumarate	E00545	23665634	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Water	E00035	962	Solvent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Bedaquiline Fumarate eq 100mg base tablet	eq 100mg base	Tablet	Oral
Bedaquiline 100 mg tablet	100 mg	Oral Tablet	Oral
Bedaquiline Fumarate eq 20mg base tablet	eq 20mg base	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6	Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
7	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
8	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
9	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
10	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
11	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
13	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
14	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
15	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16	Cerner Multum, Inc. "Australian Product Information.".
17	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
18	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
21	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
22	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
23	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
24	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
25	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
26	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
27	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
28	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
29	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
30	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
31	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
32	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.